64 related articles for article (PubMed ID: 20051950)
1. Co-detection of members of the urokinase plasminogen activator system in tumour tissue and serum correlates with a poor prognosis for soft-tissue sarcoma patients.
Taubert H; Würl P; Greither T; Kappler M; Bache M; Lautenschläger C; Füssel S; Meye A; Eckert AW; Holzhausen HJ; Magdolen V; Kotzsch M
Br J Cancer; 2010 Feb; 102(4):731-7. PubMed ID: 20051950
[TBL] [Abstract][Full Text] [Related]
2. Podocyte injury-driven intracapillary plasminogen activator inhibitor type 1 accelerates podocyte loss via uPAR-mediated β1-integrin endocytosis.
Kobayashi N; Ueno T; Ohashi K; Yamashita H; Takahashi Y; Sakamoto K; Manabe S; Hara S; Takashima Y; Dan T; Pastan I; Miyata T; Kurihara H; Matsusaka T; Reiser J; Nagata M
Am J Physiol Renal Physiol; 2015 Mar; 308(6):F614-26. PubMed ID: 25587125
[TBL] [Abstract][Full Text] [Related]
3. Serum uPAR as Biomarker in Breast Cancer Recurrence: A Mathematical Model.
Hao W; Friedman A
PLoS One; 2016; 11(4):e0153508. PubMed ID: 27078836
[TBL] [Abstract][Full Text] [Related]
4. Do coagulation or fibrinolysis reflect the disease condition in patients with soft tissue sarcoma?
Asanuma K; Nakamura T; Okamoto T; Hagi T; Kita K; Nakamura K; Matsuyama Y; Yoshida K; Asanuma Y; Sudo A
BMC Cancer; 2022 Oct; 22(1):1075. PubMed ID: 36258189
[TBL] [Abstract][Full Text] [Related]
5. Prognostic significance of the urokinase plasminogen activator system in tissue and serum of dogs with appendicular osteosarcoma.
Matsuyama A; Wood GA; Speare R; Schott CR; Mutsaers AJ
PLoS One; 2022; 17(9):e0273811. PubMed ID: 36174075
[TBL] [Abstract][Full Text] [Related]
6. Urokinase plasminogen activator predicts poor prognosis in hepatocellular carcinoma.
Niu FY; Jin C; Ma L; Shi YX; Li XS; Jiang P; Gao S; Lin JR; Song Y
J Gastrointest Oncol; 2021 Aug; 12(4):1851-1859. PubMed ID: 34532133
[TBL] [Abstract][Full Text] [Related]
7. Significance of coagulation and fibrinolysis markers for benign and malignant soft tissue tumors.
Asanuma K; Nakamura T; Hagi T; Okamoto T; Kita K; Nakamura K; Matsuyama Y; Yoshida K; Asanuma Y; Sudo A
BMC Cancer; 2021 Apr; 21(1):364. PubMed ID: 33827473
[TBL] [Abstract][Full Text] [Related]
8. Aberrant Factors of Fibrinolysis and Coagulation in Pancreatic Cancer.
Fang L; Xu Q; Qian J; Zhou JY
Onco Targets Ther; 2021; 14():53-65. PubMed ID: 33442266
[TBL] [Abstract][Full Text] [Related]
9. Rapid detection of urokinase plasminogen activator using flexible paper-based graphene-gold platform.
Sharma B; Parajuli P; Podila R
Biointerphases; 2020 Feb; 15(1):011004. PubMed ID: 32019314
[TBL] [Abstract][Full Text] [Related]
10. Determination of urokinase-type plasminogen activator serum levels in healthy and oncologic cats.
Viegas C; de Matos AJ; Leite-Martins LR; Viegas I; Ferreira RRF; Gregório H; Santos AA
Can J Vet Res; 2020 Jan; 84(1):60-66. PubMed ID: 31949329
[TBL] [Abstract][Full Text] [Related]
11. Expression of urokinase-type plasminogen activator system in non-metastatic prostate cancer.
Kimura S; D'Andrea D; Iwata T; Foerster B; Janisch F; Parizi MK; Moschini M; Briganti A; Babjuk M; Chlosta P; Karakiewicz PI; Enikeev D; Rapoport LM; Seebacher V; Egawa S; Abufaraj M; Shariat SF
World J Urol; 2020 Oct; 38(10):2501-2511. PubMed ID: 31797075
[TBL] [Abstract][Full Text] [Related]
12. Elevated levels of serum urokinase plasminogen activator predict poor prognosis in hepatocellular carcinoma after resection.
Tsai MC; Yen YH; Chang KC; Hung CH; Chen CH; Lin MT; Hu TH
BMC Cancer; 2019 Dec; 19(1):1169. PubMed ID: 31791275
[TBL] [Abstract][Full Text] [Related]
13. The prognostic relevance of urokinase-type plasminogen activator (uPA) in the blood of patients with metastatic breast cancer.
Banys-Paluchowski M; Witzel I; Aktas B; Fasching PA; Hartkopf A; Janni W; Kasimir-Bauer S; Pantel K; Schön G; Rack B; Riethdorf S; Solomayer EF; Fehm T; Müller V
Sci Rep; 2019 Feb; 9(1):2318. PubMed ID: 30783124
[TBL] [Abstract][Full Text] [Related]
14. Multifaceted Role of the Urokinase-Type Plasminogen Activator (uPA) and Its Receptor (uPAR): Diagnostic, Prognostic, and Therapeutic Applications.
Mahmood N; Mihalcioiu C; Rabbani SA
Front Oncol; 2018; 8():24. PubMed ID: 29484286
[TBL] [Abstract][Full Text] [Related]
15. Prognostic implications of the co-detection of the urokinase plasminogen activator system and osteopontin in patients with non-small-cell lung cancer undergoing radiotherapy and correlation with gross tumor volume.
Ostheimer C; Evers C; Bache M; Reese T; Vordermark D
Strahlenther Onkol; 2018 Jun; 194(6):539-551. PubMed ID: 29340706
[TBL] [Abstract][Full Text] [Related]
16. CMG2 Expression Is an Independent Prognostic Factor for Soft Tissue Sarcoma Patients.
Greither T; Wedler A; Rot S; Keßler J; Kehlen A; Holzhausen HJ; Bache M; Würl P; Taubert H; Kappler M
Int J Mol Sci; 2017 Dec; 18(12):. PubMed ID: 29215551
[TBL] [Abstract][Full Text] [Related]
17. The fibrogenic actions of lung fibroblast-derived urokinase: a potential drug target in IPF.
Schuliga M; Jaffar J; Harris T; Knight DA; Westall G; Stewart AG
Sci Rep; 2017 Jan; 7():41770. PubMed ID: 28139758
[TBL] [Abstract][Full Text] [Related]
18. The urokinase receptor-derived cyclic peptide [SRSRY] suppresses neovascularization and intravasation of osteosarcoma and chondrosarcoma cells.
Ingangi V; Bifulco K; Yousif AM; Ragone C; Motti ML; Rea D; Minopoli M; Botti G; Scognamiglio G; Fazioli F; Gallo M; De Chiara A; Arra C; Grieco P; Carriero MV
Oncotarget; 2016 Aug; 7(34):54474-54487. PubMed ID: 27323409
[TBL] [Abstract][Full Text] [Related]
19. Prognostic impact of urokinase-type plasminogen activator system components in clear cell renal cell carcinoma patients without distant metastasis.
Fuessel S; Erdmann K; Taubert H; Lohse-Fischer A; Zastrow S; Meinhardt M; Bluemke K; Hofbauer L; Fornara P; Wullich B; Baretton G; Magdolen V; Wirth MP; Kotzsch M
BMC Cancer; 2014 Dec; 14():974. PubMed ID: 25519168
[TBL] [Abstract][Full Text] [Related]
20. Tumour microenvironments induce expression of urokinase plasminogen activator receptor (uPAR) and concomitant activation of gelatinolytic enzymes.
Magnussen S; Hadler-Olsen E; Latysheva N; Pirila E; Steigen SE; Hanes R; Salo T; Winberg JO; Uhlin-Hansen L; Svineng G
PLoS One; 2014; 9(8):e105929. PubMed ID: 25157856
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
